HHS Ditches mRNA Vaccine Program Amidst Safety Concerns, Biotech Firms and Academic Giants Face $500M Cutback
HHS is halting their mRNA vaccine development under BARDA, citing lower efficacy against respiratory infections. Contracts with biotech firms are being canceled or downscaled, but certain projects will complete for fiscal reasons.












-2.webp?max-h=350&w=550&fit=crop)